BIO-Europe Spring® 2017: Prexton CEO on future for novel Parkinson's therapy

April 7, 2017
As Prexton Therapeutics prepares to move its lead compound foliglurax into Phase II trials as a symptomatic treatment for Parkinson’s disease, CEO Francois Conquet talks to Scrip about the company's technology and its future. Prexton raised EUR 29 million via a series B financing earlier this year to progress foliglurax, a metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM), into Phase II trials. A European Phase II trial is expected to enroll its first patient in June and will be completed by the end of 2018. A US trial is also planned. After Phase II, Conquet hopes the company will be able to license the compound to a big pharma for Phase III development.
Previous Video
BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans
BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans

During BIO-Europe Spring 2017 in Barcelona, Eugene Zhukovsky, chief scientific officer at Biomunex speaks t...

Next Video
BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities
BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities

Seventure Partners’ Eric de la Fortelle explains to Informa Pharma Intelligence’s Mike Ward how the venture...